Related Experiment Video

Updated: May 24, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Gene therapy for heart failure

Lisa Tilemann1, Kiyotake Ishikawa, Thomas Weber

  • 1Cardiovascular Research Center, Mount Sinai Medical Center, New York, NY 10029, USA.

Circulation Research
|March 3, 2012
PubMed

Insights

Gene therapy offers a promising new treatment for advanced heart failure, a leading cause of death. Recent clinical trials show safe and effective gene transfer targeting SERCA2a, heralding a new era in heart failure treatment.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Biotechnology

Background:

  • Congestive heart failure (CHF) is a major cause of mortality, with limited treatment options for advanced stages.
  • Current therapies can only slow CHF progression, highlighting the need for novel therapeutic strategies.
  • Understanding the molecular underpinnings of myocardial dysfunction is crucial for developing new treatments.

Purpose of the Study:

  • To explore gene therapy as a viable alternative for treating heart failure.
  • To investigate the potential of targeting molecular pathways involved in myocardial dysfunction.
  • To assess the safety and efficacy of gene transfer technologies in heart failure.

Main Methods:

  • Focus on gene therapy approaches for heart failure.
  • Utilize advancements in understanding the molecular basis of heart failure.
  • Employ evolving gene transfer technologies for therapeutic delivery.

Main Results:

  • A Phase 2 clinical trial targeting the sarcoplasmic reticulum calcium ATPase pump (SERCA2a) demonstrated successful and safe outcomes.
  • Phase 1 trials have commenced, further evaluating gene therapy for heart failure.
  • Gene therapy is emerging as a feasible treatment modality for heart failure.

Conclusions:

  • Gene therapy represents a new frontier in treating congestive heart failure.
  • Targeting specific molecular mechanisms, like SERCA2a, shows therapeutic potential.
  • Advancements in gene transfer technology pave the way for effective gene-based heart failure treatments.

More Related Videos

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...